Pharmaceuticals & Biotech Canadian Community

Catalysts Federal rescheduling of marijuana from Schedule I to Schedule III of the Controlled Substances Act is an inevitability from a scientific and sociopolitical perspective within five years. Rescheduling will eliminate the application of the punitive s.Read more

Cybin’s aggressive analyst price targets make sense when you view the company through a true late-stage biotech lens rather than a speculative psychedelic stock. With more than US$225 million in cash after retiring all debt, Cybin is now one of the only fully funded companies in the entire sector with enough runway to complete multiple Phase 3 trials and deliver two major clinical readouts—Phase 2 CYB004 data in Q1 2026 and pivotal Phase 3 CYB003 results in Q4 2026.Read more

BioNxt is developing two platform technologies: a sublingual thin-film technology (ODF) for smart drug delivery and a novel chemotherapy platform in which the active ingredient is activated directly in the tumor—targeting and killing cancer cells while sparing healthy cells. The ODF technology is protected by a European broad patent (intention-to-grant, May 2025), covering a wide range of sublingual active ingredients and is being nationalized in key markets.Read more

Organigram Holdings Inc. has seen some significant developments in the past four months: ✓ Acquisition of Motif Labs: In December 2024, Organigram acquired Motif Labs, a Canadian cannabis company, for C$90 million upfront.Read more

It sounds like Cybin (CYBN) is gaining serious traction in the psychedelic therapy space! Guggenheim’s $35 price target is pretty aggressive, considering the stock is currently trading at a fraction of that.Read more

Key Takeaways Dependence on regulatory progress and geographic concentration makes growth and margins vulnerable to shifting laws, competition, and price compression in key U.S. markets. Industry oversupply, persistent stigma, and potential new competitors could limit sales momentum, erode margins, and challenge long-term earnings resilience.Read more

Key Takeaways Operational leverage and internalized management are set to unlock stronger margins and higher earnings, surpassing current market forecasts. Expanding royalty opportunities and aggressive capital deployment position the Trust for sustained, above-trend revenue growth and enhanced competitive advantage.Read more

Key Takeaways Intensifying regulatory scrutiny, price compression, and new competitors threaten margins, market share, and long-term profitability. Heavy investment and macroeconomic headwinds risk ongoing negative cash flow and shrinking shareholder value.Read more

Key Takeaways Upcoming patent expiries and growing generic competition threaten HLS's ability to sustain premium pricing, top-line sales, and long-term financial stability. Overreliance on a limited product range and lack of early-stage pipeline heighten the risk of volatile earnings and revenue contraction.Read more